LCP1 is a prognostic biomarker correlated with immune infiltrates in gastric cancer.

Research paper by Qingwen Q Zeng, Leyan L Li, Zongfeng Z Feng, Lianghua L Luo, Jianbo J Xiong, Zhigang Z Jie, Yi Y Cao, Zhengrong Z Li

Indexed on: 01 Oct '20Published on: 29 Sep '20Published in: Cancer biomarkers : section A of Disease markers


Previous studies have identified LCP1 as a diagnostic and prognostic marker in several cancers. However, the role of LCP1 in gastric cancer (GC) and its effect on tumor immune infiltration remain unclear. The aim was to explore the role of LCP1 in GC and its effect on tumor immune infiltration. We explored the expression of LCP1 relative to clinicopathology in GC patients by bioinformatics analysis and immunohistochemistry. Using cBioportal database, we analyzed the characteristic genetic variations of LCP1 in GC. In addition, we evaluated the correlation between LCP1 expression and tumor-infiltrating lymphocytes (TILs) using R software, TIMER and TISIDB databases. Finally, we analyzed the biological functions in which LCP1 may participate and the signaling pathways it may regulate. Here, we showed that LCP1 expression is significantly correlated with tumor aggressiveness and poor prognosis in GC patients. Additionally, the results indicated that LCP1 was associated with TILs, including both immunosuppressive and immunosupportive cells, and was strongly correlated with various immune marker sets in GC. GSEA analysis demonstrated that LCP1 expression played an important role in lymphocyte formation and immune reaction. LCP1 may be a potential prognostic biomarker for GC patients and a marker for tumor immunotherapy.